Compounds > domperidone

domperidone and pramipexole

domperidone has been researched along with pramipexole in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Grosset, D; Grosset, K; Macphee, G; Needleman, F1
Ginovart, N; Ko, F; McCormick, P; Seeman, P; Willeit, M1
Bradshaw, CM; Hou, RH; Langley, RW; Samuels, ER; Szabadi, E1

Other Studies

5 other study(ies) available for domperidone and pramipexole

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:11

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles

2004
Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
    Synapse (New York, N.Y.), 2005, Volume: 58, Issue:2

    Topics: Animals; Benzothiazoles; Binding, Competitive; Brain; Cells, Cultured; Cricetinae; Domperidone; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Mice; Neurons; Oxazines; Parkinson Disease; Pramipexole; Radioligand Assay; Rats; Receptors, Dopamine D2; Receptors, Dopamine D3; Synapses; Synaptic Transmission; Thiazoles; Tritium

2005
Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers.
    British journal of clinical pharmacology, 2007, Volume: 64, Issue:5

    Topics: Adolescent; Adult; Autonomic Nervous System; Benzothiazoles; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Endocrine System; Humans; Male; Pramipexole; Psychophysiology; Pupil; Reflex, Pupillary; Treatment Outcome

2007